Relevant BNF section: BNF 2.4
Chronic obstructive pulmonary disease (COPD) is a disabling condition characterised by largely irreversible airflow obstruction, and affects over 3 million people in the UK.1 Due in large part to shared risk factors - notably smoking - patients with COPD often also have cardiovascular diseases, such as ischaemic heart disease and heart failure.2 3 In these conditions, beta-blockers are valuable management options with proven benefits on symptoms and mortality.4–6 Historically, however, clinicians have been reluctant to prescribe beta-blockers for patients with co-existing COPD, due to fear of provoking bronchoconstriction.3 Moreover, such patients have typically been excluded from trials of beta-blockers, raising additional concerns about the basis for treating them with these drugs.7 However, withholding beta-blocker therapy might lead to suboptimal treatment for cardiovascular disease among these patients. Here we review the efficacy and safety of beta-blockers in patients with COPD.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.